Noticias sobre VIH/SIDA

HIV capsid inhibitor may offer long-term viral suppression

Aidsmap news - English - Lun, 11/03/2019 - 10:00am
An experimental HIV capsid inhibitor appears safe and may be able to be administered once every three months or less, according to results from an early clinical trial presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2019) last week in Seattle. GS-6207, Gilead Sciences' first-in-class capsid inhibitor, interferes with the assembly and disassembly
Categorías: VIH/SIDA

One in six South Africans drug-resistant before starting HIV treatment

Aidsmap news - English - Lun, 11/03/2019 - 6:30am
One in six people not on treatment in a large South African household survey already had drug-resistant HIV and more than half of those on treatment had resistance to at least one drug, researchers reported last week at the Conference on Retroviruses and Opportunistic Infections in Seattle. The sobering assessment of the extent of
Categorías: VIH/SIDA

People stay on PrEP for 14 months on average in the US, study finds

Aidsmap news - English - Dom, 10/03/2019 - 3:40pm
Whether HIV pre-exposure prophylaxis (PrEP) is effective depends on whether people take it appropriately, at the times when they are at risk of HIV. But we know surprisingly little about how people receiving PrEP through health services take PrEP, in terms of whether they take it correctly, how long they take it for, and
Categorías: VIH/SIDA

Are CD4 counts still useful in the 'treat all' era?

Aidsmap news - English - Vie, 08/03/2019 - 8:30pm
CD4 cell testing before starting treatment is still essential even in the era of 'treat all' guidelines, two studies from southern Africa presented at the Conference on Retroviruses and Opportunistic Infections in Seattle this week have concluded. CD4 cell counts measure the health of the immune system and the degree of damage caused by
Categorías: VIH/SIDA

Multiple benefits to scaling up universal test and treat in Africa

Aidsmap news - English - Vie, 08/03/2019 - 7:50pm
As well as the important findings of PopART, the largest HIV prevention trial ever conducted, this week’s Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle heard about several other studies from African countries which have scaled up universal testing and universal treatment. The studies showed the multiple benefits of these interventions.  
Categorías: VIH/SIDA

Tercer Boletín Especial CROI 2019: Viernes

El tratamiento antirretroviral inyectable de acción prolongada mantiene el control de la carga viral del VIH

Susan Swindells y Chloe Orkin en su presentación en la CROI 2019. Foto: Liz Highleyman.

Una combinación inyectable de dos fármacos antirretrovirales de acción prolongada, administrada una vez al mes, obtuvo una tasa muy reducida de fracaso terapéutico y ofreció un perfil de seguridad favorable, según los resultados de dos ensayos de fase III presentados en la Conferencia sobre Retrovirus e Infecciones Oportunistas (CROI 2019).

Categorías: VIH/SIDA

Long-acting injectable treatment maintains viral suppression

Aidsmap news - English - Vie, 08/03/2019 - 12:00pm
A combination of two long-acting injectable anti-HIV drugs taken once monthly had a very low rate of treatment failure and a favourable safety profile, according to results from two phase III trials presented yesterday at the Conference on Retroviruses and Opportunistic Infections (CROI 2019) in Seattle. Dual injections of cabotegravir, an experimental integrase inhibitor, and the
Categorías: VIH/SIDA

CROI 2019: La enfermedad pulmonar obstructiva crónica aumenta el riesgo de infarto de miocardio en personas con el VIH

gTt-VIH - La noticia del día - Vie, 08/03/2019 - 10:28am

De acuerdo con un estudio estadounidense, la enfermedad pulmonar obstructiva crónica (EPOC) aumenta el riesgo de infarto de miocardio en personas con el VIH. Los resultados han sido presentados durante la 26 Conferencia sobre Retrovirus e Infecciones Oportunistas (CROI 2019), que se clausuró ayer en Seattle (EE UU).

La EPOC es una enfermedad pulmonar común que causa dificultad para respirar. Existen dos formas principales de la EPOC: la bronquitis crónica –que implica una tos prolongada con moco– y el enfisema –que implica un daño en el tejido de los pulmones a largo plazo–. La causa principal de la EPOC es el tabaquismo. Cuanto más fume una persona, mayor probabilidad tendrá de desarrollar EPOC.

Categorías: VIH/SIDA

El Día Internacional de la Mujer, ONUSIDA exige más medidas para proteger a las adolescentes y jóvenes

UNAIDS | Press Statements - Vie, 08/03/2019 - 9:45am
Cada día, 460 niñas adolescentes contraen la infección por el VIH y cada semana 350 niñas adolescentes mueren a causa de enfermedades relacionadas con el sida
Categorías: VIH/SIDA

‘Molecular scissors’ successfully remove HIV genes from all tissues in infected monkeys

Aidsmap news - English - Vie, 08/03/2019 - 4:10am
The top story from the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle this week has been a likely second HIV cure. However the cure involved an expensive and risky therapy – a bone-marrow transplant – that would never be broadly applicable. Just as significant in the long term may be a
Categorías: VIH/SIDA

Integrase inhibitor treatment leads to greater weight gain

Aidsmap news - English - Vie, 08/03/2019 - 12:10am
More evidence that HIV integrase inhibitor treatment is associated with weight gain, and that people gain more weight after beginning treatment with an integrase inhibitor than people taking other drug classes, was presented this week at the Conference on Retroviruses and Opportunistic Infections in Seattle. Weight gain on integrase inhibitor treatment was first flagged up in
Categorías: VIH/SIDA

How many people who have used PrEP get HIV the same year? New York study finds out

Aidsmap news - English - Jue, 07/03/2019 - 10:00pm
One question often asked about PrEP use is how frequently people start PrEP while unknowingly having HIV, often because they have caught it so recently they are still in the ‘window period’ when it cannot be detected. Taking PrEP while already infected can cause HIV drug resistance, and concerns have been expressed that this
Categorías: VIH/SIDA

Chronic obstructive pulmonary disease (COPD) increases the risk of heart attack in people with HIV

Aidsmap news - English - Jue, 07/03/2019 - 9:20pm
Chronic obstructive pulmonary disease (COPD) increases the risk of heart attack in people with HIV, US researchers reported at the Conference on Retroviruses and Opportunistic Infections in Seattle this week.COPD refers to chronic lung disease that causes breathing difficulties (including emphysema and bronchitis). COPD tends to be progressive and is mainly caused by
Categorías: VIH/SIDA

The length of time Americans with HIV remain infectious is falling, but slowly

Aidsmap news - English - Jue, 07/03/2019 - 9:10pm
In 2016, more than half of people with HIV in the United States took more than three years to be diagnosed, and more than five months after diagnosis to be virally suppressed, the Conference on Retroviruses and Opportunistic Infections was told today in Seattle.More progress has been made in reducing time from diagnosis to
Categorías: VIH/SIDA

CROI 2019: Descovy® se muestra no inferior a Truvada® como profilaxis preexposición al VIH

gTt-VIH - La noticia del día - Jue, 07/03/2019 - 5:27pm

De acuerdo con los resultados del estudio DISCOVER, Descovy® (tenofovir alafenamida/emtricitabina; TAF/FTC) se muestra no inferior a Truvada® (tenofovir disoproxil fumarato/emtricitabina; TDF/FTC) como profilaxis preexposición al VIH (PrEP). Además, tal como era de esperar, TAF/FTC presenta un perfil de seguridad renal y ósea más favorable que TDF/FTC. Estos hallazgos se han dado a conocer durante la 26 Conferencia sobre Retrovirus e Infecciones Oportunistas (CROI 2019), que está teniendo lugar esta semana en Seattle (EE UU).

Hasta el momento, Truvada® es el único fármaco antirretroviral autorizado para su uso como PrEP en personas en alto riesgo de infección. Además, existe un equivalente farmacéutico genérico (EFG) en muchos países europeos cuya indicación también incluye la profilaxis preexposición al VIH. Entre las personas que toman TDF/FTC como PrEP, se ha podido observar que es un combinación muy eficaz y tolerable; no obstante, TDF se asocia con anomalías óseas y renales en una minoría de personas que lo toman y su uso está contraindicado en aquellas que tienen problemas renales preexistentes (un filtrado glomerular estimado menor de 50 ml/min).

Categorías: VIH/SIDA

Neural tube defects and integrase inhibitors: still waiting for stronger evidence

Aidsmap news - English - Jue, 07/03/2019 - 1:20pm
Researchers are still unable to determine if exposure to integrase inhibitors around conception and in early pregnancy increases the risk of neural tube defects in infants, research presented this week at the Conference on Retroviruses and Opportunistic Infections shows. Concerns about the risk were raised in 2018 after a higher rate of neural tube defects
Categorías: VIH/SIDA

Hepatitis C drops among HIV-positive London gay men after direct-acting antiviral scale-up

Aidsmap news - English - Jue, 07/03/2019 - 11:30am
New cases of hepatitis C virus (HCV) infection among HIV-positive gay and bisexual men seen at three clinics in London have declined by nearly 70% since 2015, according to a presentation yesterday at the Conference on Retroviruses and Opportunistic Infections (CROI 2019) in Seattle. The drop is largely attributable to regular HCV screening and
Categorías: VIH/SIDA

Primer Boletín Especial CROI 2019: Miércoles

Un paciente londinense presenta una remisión prolongada del VIH tras un trasplante de células madre

[image caption] Ravindra Gupta, en su presentación en la CROI 2019. Foto: Liz Highleyman. [end of image caption]

Un hombre de Londres (Reino Unido) no ha presentado niveles detectables del VIH un año y medio después de interrumpir el tratamiento antirretroviral, tras haberse sometido a un trasplante de células madre de médula ósea para tratar un linfoma, según una presentación realizada en la Conferencia sobre Retrovirus e Infecciones Oportunistas (CROI 2019), que se está celebrando esta semana en la ciudad de Seattle (EE UU).

Categorías: VIH/SIDA

HIV infections lowered by 30% in universal testing and treatment study

Aidsmap news - English - Mié, 06/03/2019 - 7:50pm
Communities in southern Africa which received a door-to-door HIV testing intervention and support for linkage to care had substantially lower HIV incidence, the Conference on Retroviruses and Infections (CROI 2019) in Seattle was told today.This clear-cut effect was seen in the communities randomised to receive these interventions and treatment according to national guidelines, but as
Categorías: VIH/SIDA

Páginas